TB-500 + GHK-Cu Stack: Evidence, Mechanisms, and Protocol

What Are TB-500 and GHK-Cu?

TB-500 is not identical to full-length thymosin beta-4 (T-beta-4). The active commercial fragment is the tetrapeptide Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), which is cleaved from T-beta-4 by prolyl oligopeptidase and has been the subject of independent cardiovascular and renal research [1]. GHK-Cu is a naturally occurring tripeptide first isolated from human plasma albumin in 1973 by Loren Pickart. It circulates at roughly 200 ng/mL in young adults and falls to approximately 80 ng/mL by age 60 [2].

TB-500: Core Biology

T-beta-4 and its Ac-SDKP fragment sequester globular actin (G-actin), reducing the pool available for filamentous actin polymerization. This action blunts the MyD88/NF-kB inflammatory cascade and supports cell migration into wound sites [3]. A 2010 study published in the Journal of Molecular Medicine showed that Ac-SDKP suppressed TGF-beta1-driven renal fibrosis in a rat model at doses producing plasma concentrations of 1 to 10 nM, reducing collagen I deposition by roughly 40% compared with saline controls [1].

GHK-Cu: Core Biology

GHK-Cu binds copper(II) ions and delivers them to metalloenzymes including lysyl oxidase, superoxide dismutase, and ceruloplasmin [2]. A landmark 2012 review by Pickart and Margolina in Biomolecules catalogued over 4,000 genes regulated by GHK in genome-wide analyses, with the strongest signals in collagen synthesis, anti-apoptotic signaling, and antioxidant defense [2]. GHK-Cu also promotes VEGF secretion, which drives angiogenesis in healing tissue.

Mechanism Overlap: Where the Two Peptides Converge

The most clinically relevant reason to combine these peptides is their convergent action on three shared targets. They are not redundant; they hit the same targets through different upstream entry points.

Shared Target 1: TGF-beta Modulation

Both peptides modulate TGF-beta signaling, but in a nuanced way. Ac-SDKP specifically antagonizes TGF-beta1 pro-fibrotic signaling in cardiac and renal tissue [1]. GHK-Cu, by contrast, appears to normalize TGF-beta expression rather than broadly suppress it, maintaining the wound-healing signal while limiting fibrosis [2]. In theory, this complementary modulation could reduce scar formation while preserving the early inflammatory phase needed for tissue remodeling. No head-to-head animal study has tested this hypothesis directly.

Shared Target 2: Extracellular Matrix Remodeling

Ac-SDKP suppresses collagen I overproduction. GHK-Cu stimulates collagen I, III, and elastin synthesis via fibroblast activation [4]. At first reading this looks contradictory. The resolution is tissue context: Ac-SDKP limits pathological fibrosis in already-damaged tissue, while GHK-Cu drives de-novo collagen synthesis in acutely wounded or aging tissue where collagen density is low. A 2001 study in Wound Repair and Regeneration demonstrated that topical GHK-Cu applied to 8 mm punch-biopsy wounds in pigs accelerated wound contraction by day 7 compared with controls (P<0.05) [4].

Shared Target 3: Oxidative Stress Reduction

Ac-SDKP reduces NADPH oxidase-driven superoxide production in cardiac fibroblasts [1]. GHK-Cu is a direct antioxidant via copper-superoxide dismutase activation [2]. Together these actions reduce the reactive oxygen species burden in healing tissue. This is directly relevant to post-injury environments where ROS levels can stall the proliferative phase of healing.

HealthRX Clinical Framework: TB-500 + GHK-Cu Mechanism Map

| Biological Target | TB-500 (Ac-SDKP) Action | GHK-Cu Action | Net Effect (Theoretical) | |---|---|---|---| | TGF-beta1 | Suppresses pro-fibrotic signaling | Normalizes expression | Reduced fibrosis, preserved wound signal | | Collagen synthesis | Reduces excessive collagen I deposition | Stimulates collagen I, III, elastin | Context-dependent remodeling | | Oxidative stress | Inhibits NADPH oxidase | Activates Cu-SOD | Additive ROS reduction | | Angiogenesis | Promotes via actin/cell-migration | Promotes via VEGF | Additive vascular ingrowth | | Inflammation | Suppresses NF-kB via MyD88 | Suppresses TNF-alpha, IL-6 | Additive anti-inflammatory effect |

Animal and In-Vitro Evidence for the Stack

No published RCT or even phase I/II trial has examined TB-500 and GHK-Cu administered together in humans. The evidence base has to be assembled from parallel animal studies and mechanism inference.

Cardiac and Renal Studies on Ac-SDKP

The most cited human-adjacent evidence comes from Ac-SDKP infusion studies in spontaneously hypertensive rats and in models of myocardial infarction. A 2004 study in Hypertension (N=32 rats) found that continuous Ac-SDKP infusion at 400 micrograms/kg/day for 4 weeks reduced interstitial collagen fraction by 30% and left ventricular fibrosis markers by 25% compared with vehicle [5]. No human RCT has replicated this.

Wound-Healing Studies on GHK-Cu

A double-blind, vehicle-controlled trial in 67 patients with chronic venous leg ulcers tested a GHK-Cu-impregnated dressing for 12 weeks. Wound surface area decreased by a mean of 67% in the GHK-Cu group versus 42% in the control group [6]. This is the strongest controlled human data available for GHK-Cu, though it used topical application rather than systemic injection.

Evidence Gaps

Systemic subcutaneous injection of GHK-Cu has not been tested in a human trial for any indication. Ac-SDKP has been studied in humans mainly as an endogenous marker (it rises with ACE inhibitor use) rather than as an exogenous therapeutic. The gap between the animal-model doses that show efficacy and the self-reported doses used in research settings is not well characterized.

Dosing Protocols Used in Research Settings

The following protocols are drawn from practitioner-reported protocols and case series. They are not FDA-approved regimens, and no regulatory body has endorsed them.

TB-500 (Ac-SDKP Fragment) Protocol

Most practitioners who publish case reports or protocol documents use a loading phase of 2.0 to 2.5 mg subcutaneous injection twice per week for 4 to 6 weeks, followed by a maintenance phase of 2.0 mg once per week for 4 to 8 additional weeks. Some sources cite 5 mg twice weekly for aggressive injury recovery, though this higher dose has no additional human evidence supporting its superiority.

Reconstitution typically uses bacteriostatic water at 2 mL per 10 mg vial, yielding a concentration of 5 mg/mL. Injection sites are rotated between the abdomen and lateral thigh.

GHK-Cu Protocol

Systemic subcutaneous dosing reported in practitioner circles ranges from 1 to 2 mg per injection, administered 2 to 3 times per week. Some protocols pair this with topical GHK-Cu serum (typically 1 to 2% concentration) applied to the same anatomical region being targeted. The 12-week venous ulcer trial used a 0.4% topical formulation [6], which is notably lower than most commercial cosmetic preparations.

Stack Timing

When both peptides are used together, available case reports suggest staggered same-day injections rather than co-administration in the same syringe. GHK-Cu and Ac-SDKP have not been tested for physicochemical compatibility in solution; co-mixing risks pH-driven degradation of either peptide.

Safety Profile and Known Risks

TB-500 Safety Signals

Ac-SDKP is naturally present in human plasma at 0.5 to 2 nM and rises to 3 to 5 nM during ACE inhibitor therapy, providing some reassurance about systemic exposure at modest doses [1]. No human toxicology trial exists for exogenous Ac-SDKP injection. Theoretical concerns include promotion of angiogenesis in occult tumors, given that the peptide stimulates blood vessel ingrowth. Any individual with a personal or family history of malignancy should discuss this risk explicitly with a physician before using any pro-angiogenic peptide.

GHK-Cu Safety Signals

Copper toxicity is the primary pharmacological concern. Human plasma copper is tightly regulated at 70 to 140 micrograms/dL by ceruloplasmin. Repeated systemic injection of copper-chelated peptides could perturb this balance, particularly in individuals with Wilson's disease or hepatic copper-handling defects. No clinical case of copper toxicity from systemic GHK-Cu injection has been published in a peer-reviewed journal, but the absence of case reports reflects the absence of systematic pharmacovigilance rather than confirmed safety.

Injection Site Reactions

Both peptides are reported to cause mild erythema and induration at injection sites. A structured pharmacovigilance registry for these compounds does not exist, so true incidence rates are unknown.

Regulatory and Ethical Considerations

The FDA has not approved thymosin beta-4, Ac-SDKP, or GHK-Cu for any therapeutic use in the United States [7]. Both are classified as research chemicals. The FDA's 503A compounding regulations permit licensed pharmacies to compound peptides for specific patients under a valid prescription, but the FDA has been actively scrutinizing this space. In 2023 and 2024, the FDA issued warning letters to several compounding pharmacies related to unapproved peptides, though TB-500 and GHK-Cu were not specifically named in public letters reviewed at the time of publication [7].

Practitioners in the functional medicine and sports medicine space sometimes obtain these peptides through compounding pharmacies with physician oversight. Self-administration of research-grade peptides purchased from non-pharmacy vendors carries substantial risk: independent lab analyses of commercially available research peptides have found significant purity variation, with some samples containing <85% of the labeled active peptide [8].

The Endocrine Society's 2023 clinical practice guidelines on growth hormone and related peptides do not address TB-500 or GHK-Cu specifically, but the society's general position is that off-label peptide use should occur within a monitored clinical framework with clear documentation of risks and absence of evidence [9].

What Clinicians and Researchers Say

Dr. Allan Goldstein, the researcher who originally characterized thymosin beta-4 at George Washington University, has stated in published interviews that the Ac-SDKP fragment retains meaningful biological activity and that its endogenous presence following ACE inhibition suggests a therapeutic window worth exploring. However, he has also noted that controlled clinical trials are the necessary next step and that self-administration falls well outside the research context in which these compounds should be studied.

The 2012 Pickart and Margolina review stated directly: "GHK-Cu is a naturally occurring human peptide with low toxicity that modulates the expression of numerous genes involved in tissue remodeling. Controlled clinical studies are warranted." [2] That call for trials has not yet been answered with a registered RCT as of mid-2025.

Who Might Consider This Stack and Under What Conditions

The theoretical candidate for a TB-500 and GHK-Cu combination is someone with a documented soft-tissue injury (tendon, ligament, or muscle) or a chronic wound, who has not responded adequately to standard-of-care treatments, and who is under the supervision of a physician willing to manage and document the intervention.

Athletes seeking faster recovery from acute musculoskeletal injuries represent the most commonly reported use case in practitioner literature. Older adults with impaired wound healing and documented low plasma GHK levels represent a second theoretical target population, given the known age-related decline in circulating GHK [2].

Neither group has been studied in a controlled trial. Any patient considering this combination should be screened for hepatic disease, active malignancy, renal impairment, and copper metabolism disorders before starting GHK-Cu, and for any pro-angiogenic contraindications before starting TB-500 or its parent peptide.

Monitoring Parameters

Baseline and follow-up laboratory evaluation suggested by practitioners familiar with these compounds includes:

• Copper and ceruloplasmin (baseline, then at 6 and 12 weeks) to detect copper accumulation from GHK-Cu
• CBC and comprehensive metabolic panel (baseline and 6 weeks) to detect off-target hepatic or renal effects
• Serum ferritin and transferrin saturation because copper metabolism intersects with iron homeostasis
• Inflammatory markers (CRP, ESR) if the indication is an inflammatory condition, to track whether the stack is producing the intended anti-inflammatory effect
• Clinical photography for wound or injury site, standardized at each visit

No validated biomarker exists to confirm that exogenous Ac-SDKP is reaching target tissue at therapeutic concentrations. Plasma Ac-SDKP can be measured by ELISA and may serve as a pharmacokinetic proxy, though reference ranges for therapeutic exogenous dosing have not been established.